SCHEMBL4752149

SCHEMBL4752149

CCOC(=O)/C=C/c1ccc(-c2ccccc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.69
CA7 P43166 2/20 0.69
CA9 Q16790 2/20 0.69
CA14 Q9ULX7 2/20 0.69
CA1 P00915 1/20 0.69
CA2 P00918 1/20 0.69
MGLL Q99685 2/20 0.62
CYP3A4 P08684 1/20 0.60
TTR P02766 1/20 0.59
DPP4 P27487 1/20 0.59
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
LMNA P02545 1/20 0.55
AKR1B10 O60218 3/20 0.55
AKR1B1 P15121 3/20 0.55
CA4 P22748 1/20 0.55
CA6 P23280 1/20 0.55
CA5A P35218 1/20 0.55
CA5B Q9Y2D0 1/20 0.55
PTGS2 P35354 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4752151 1.00 CA12 (0.69) CA12CA7CA9CA14CA1
Ethyl Cinnamate SCHEMBL28775813 0.91 CA12 (0.75) CA12CA7CA9CA14CA1
Ethyl Cinnamate SCHEMBL12001792 0.90 CA12 (0.72) CA12CA7CA9CA14CA1
Ethyl Cinnamate SCHEMBL1866942 0.90 CA12 (0.72) CA12CA7CA9CA14CA1
Ethyl Cinnamate SCHEMBL112445 0.90 CA12 (0.72) CA12CA7CA9CA14CA1
Ethyl Cinnamate SCHEMBL112446 0.90 CA12 (0.72) CA12CA7CA9CA14CA1
Ethyl Cinnamate SCHEMBL27877727 0.88 CA12 (0.70) CA12CA7CA9CA14CA1
Ethyl Cinnamate SCHEMBL27295428 0.88 CA12 (0.70) CA12CA7CA9CA14CA1
Ethyl Cinnamate SCHEMBL28542490 0.88 CA12 (0.70) CA12CA7CA9CA14CA1
Ethyl Cinnamate SCHEMBL27295429 0.88 CA12 (0.70) CA12CA7CA9CA14CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3208301-B1 RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME TOSOH CORP (JP) 2019-04-03 EP claimed
US-10126478-B2 Resin composition and optical compensation film using same TOSOH CORPORATION (JP) 2018-11-13 US claimed
US-20170242174-A1 RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME TOSOH CORPORATION (JP) 2017-08-24 US claimed
EP-3208301-A1 RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME Tosoh Corporation (JP) 2017-08-23 EP claimed
CN-106795327-A Resin composition and optical compensation film using the same 东曹株式会社 2017-05-31 CN claimed
CN-113135816-A Method for synthesizing photoactive bromohydrin compound 常州大学 2021-07-20 CN disclosed
CN-106795327-B Resin composition and optical compensation film using the same 东曹株式会社 2019-08-30 CN disclosed
EP-3208301-B1 RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME TOSOH CORP (JP) 2019-04-03 EP disclosed
US-10126478-B2 Resin composition and optical compensation film using same TOSOH CORPORATION (JP) 2018-11-13 US disclosed
US-20170242174-A1 RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME TOSOH CORPORATION (JP) 2017-08-24 US disclosed
EP-3208301-A1 RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME Tosoh Corporation (JP) 2017-08-23 EP disclosed
CN-106795327-A Resin composition and optical compensation film using the same 东曹株式会社 2017-05-31 CN disclosed
WO-2008153286-A2 AROMATIC DIAMINES WITH A PHOTOREACTIVE AROMATIC SIDE GROUP, POLYAMIC ACID PHOTO-ALIGNMENT LAYERS WITH THEM AND METHOD FOR PREPARING LIQUID CRYSTAL CELLS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-12-18 WO disclosed
US-6867218-B2 Compounds, their preparation and use NOVO NORDISK A/S (DK) 2005-03-15 US disclosed
US-20030195200-A1 Compounds, their preparation and use VTVX HOLDINGS II LLC 2003-10-16 US disclosed
US-6555577-B1 For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
EP-1254101-A1 PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY Novo Nordisk A/S (DK) 2002-11-06 EP disclosed
WO-2001055085-A1 PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY NOVO NORDISK A/S (DK) 2001-08-02 WO disclosed
WO-1996027598-A1 A METHOD OF PREPARING A RODENTICIDE/ANTICOAGULANT COMPOUND IMPLICO B.V. (NL) 1996-09-12 WO disclosed
US-4335054-A Process for the preparation of alkenylbenzenecarboxylic acid derivatives and alkenylnaphthalenecarboxylic acid derivatives CIBA-GEIGY CORPORATION (US) 1982-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195200-A1 Compounds, their preparation and use PPARG, PPARA, PPARD CA12 4495/4885CA7 3814/4885CA9 3914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.